×
PMV Pharmaceuticals Common Stock Net 2019-2025 | PMVP
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
PMV Pharmaceuticals common stock net from 2019 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
PMV Pharmaceuticals Common Stock Net 2019-2025 | PMVP
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
PMV Pharmaceuticals common stock net from 2019 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$79.5B
Zoetis (ZTS)
$68B
Daiichi Sankyo, - (DSNKY)
$46.9B
Takeda Pharmaceutical (TAK)
$46.6B
BeOne Medicines - (ONC)
$32.5B
Sandoz Group AG (SDZNY)
$26.5B
Summit Therapeutics (SMMT)
$20.5B
Merck (MKKGY)
$17.3B
Shionogi (SGIOY)
$14.6B
United Therapeutics (UTHR)
$13.8B
Neurocrine Biosciences (NBIX)
$13B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$11.1B
Stevanato Group S.p.A (STVN)
$8.5B
Corcept Therapeutics (CORT)
$7.2B
Grifols, S.A (GRFS)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.7B
Madrigal Pharmaceuticals (MDGL)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$3.1B
Crinetics Pharmaceuticals (CRNX)
$2.8B
NewAmsterdam Pharma (NAMS)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Procaps Group, S.A (PROCF)
$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.9B
BioCryst Pharmaceuticals (BCRX)
$1.8B